Regeneron's Skin-Clearing Drug Hits Goals in Late Trials
- Dupilumab reaches targets for effectiveness, disease severity
- About 1.6 million U.S. patients with unmet treatment need
This article is for subscribers only.
Regeneron Pharmaceuticals Inc. and Sanofi said their drug to treat a serious skin condition met its goals in two final-stage trials, clearing the path toward regulatory approval in a potentially lucrative field.
More than a third of patients with a severe type of eczema known as atopic dermatitis saw their skin clear or come close in each trial of the drug, called dupilumab, the companies said Friday in a statement. Ten percent or fewer patients on placebo got the same results. Regeneron rose 5.5 percent to $380.28 at 10:34 a.m. in New York.